"Erythromycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.
| Descriptor ID |
D004917
|
| MeSH Number(s) |
D02.540.576.500.992
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Erythromycin".
Below are MeSH descriptors whose meaning is more specific than "Erythromycin".
This graph shows the total number of publications written about "Erythromycin" by people in this website by year, and whether "Erythromycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2025 | 0 | 1 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Erythromycin" by people in Profiles.
-
Gene network interaction analysis to elucidate the antimicrobial resistance mechanisms in the Clostridiumdifficile. Microb Pathog. 2023 May; 178:106083.
-
Synthesis and antibacterial evaluation of novel 11,4?-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. Eur J Med Chem. 2013 Jan; 59:209-17.
-
Synthesis and antibacterial activity of novel 4?-O-benzimidazolyl clarithromycin derivatives. Eur J Med Chem. 2011 Jul; 46(7):3105-11.
-
Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression. Eur J Pharm Sci. 2000 Nov; 12(1):63-8.
-
Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children. Pediatrics. 1992 Feb; 89(2):210-4.
-
A randomized trial of open lung biopsy versus empiric antimicrobial therapy in cancer patients with diffuse pulmonary infiltrates. J Clin Oncol. 1990 Feb; 8(2):222-9.
-
Influence of bariatric surgery on erythromycin absorption. J Clin Pharmacol. 1984 Nov-Dec; 24(11-12):523-7.
-
Emergence of multidrug-resistant Mycobacterium fortuitum during treatment. Chest. 1984 Mar; 85(3):440-1.
-
Effect of erythromycin on theophylline kinetics. J Allergy Clin Immunol. 1981 Dec; 68(6):427-31.
-
Clinical trial of topical erythromycin in inflammatory acne. Drug Intell Clin Pharm. 1981 May; 15(5):372-6.